Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients
Status:
Recruiting
Trial end date:
2029-04-01
Target enrollment:
Participant gender:
Summary
Postoperative adjuvant chemotherapy followed by immunotherapy for non-small cell lung cancer
has become a new treatment recommendation, but there are still many clinical problems to be
solved in postoperative adjuvant immunotherapy. This study aims to explore the efficacy and
safety of adjuvant chemotherapy combined with immunotherapy in patients with stage IIA-IIIA
non-small cell lung cancer after surgery. Patients who meet the protocol and sign the
informed consent form received 4 cycles of chemotherapy combined with camrelizumab, followed
by maintenance with camrelizumab until one year or the disease progressed or unacceptable
toxicity.